This round of financing is led by Huagai Capital, with participation by new investors including Suxin Venture Capital, Cherami Investment Group, ABC International, DYEE Capital, Qiaojing Eastern Investment, Baidu Venture, and Wenzhou Capital. Existing investors including CDH Venture and Growth Capital, Lake Bleu Capital, HM Capita, Panlin Capital, Shanjin Asset also participated. Start Point Advisors act as the sole financial advisor.
This multi-center trial the first POC (proof of concept) study designed by GenFleet and it's also the company's third program involving global research sites. GFH018 demonstrated excellent safety profile in phase I trial. Preclinical data also suggested antitumor effects of low-dose GFH018 in combination with PD-1 inhibitors.
Designed to enroll over 100 patients with late stage NSCLC and gastrointestinal cancer, the study will evaluate the safety/tolerability/efficacy and characterize the pharmacokinetics profile of GFH925
GenFleet Therapeutics and Innovent jointly announced that they have entered into an exclusive license agreement for the development and commercialization of GenFleet's lead KRAS G12C candidate, GFH925 in China with additional option-in rights for global development and commercialization.
GenFleet Therapeutics, a clinical-stage biotechnology company developing cutting-edge therapies in oncology and immunology worldwide, today announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for GFH925 in a multi-center phase I / II clinical trial treating advanced solid tumors among patients with KRAS G12C gene mutation.
The agreement outlines a constructive framework where GenFleet will synergize its own R&D systems with Insilco’s end-to-end AI-powered drug discovery platform and Biortus’ structural biology platform, with a view to jointly addressing significant unmet medical needs and tackling novel & difficult targets in cancer therapeutics.
May 10，2021 (Tianjin, China) -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced that the first patient has been dosed in its first-in-human trial of GFH009.
April 27, 2021 (Melbourne, Australia) -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced its first-in-human phase I trial of GFH312 has achieved dosing of subjects in the first cohort.
